

Management of Immune-Related Adverse Events in Patient with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Journal of Clinical Oncology

39, 4073-4126

DOI: [10.1200/jco.21.01440](https://doi.org/10.1200/jco.21.01440)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy. <i>JCO Oncology Practice</i> , 2022, 18, 431-444.	2.9	11
2	Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients. <i>Supportive Care in Cancer</i> , 2022, 30, 4019-4026.	2.2	10
3	Immune-mediated colitis secondary to treatment with nivolumab-ipilimumab in a patient with stage IV kidney cancer: what to do when corticosteroids fail?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.3	1
4	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 81, 414-425.	1.9	40
5	Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. <i>Oncologist</i> , 2022, 27, e223-e232.	3.7	36
6	The role of kidney biopsy in Immune Checkpoint Inhibitor-associated AKI. <i>Kidney360</i> , 2022, 3, 10.34067/KID.0000232022.	2.1	6
7	Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series. <i>Oncologist</i> , 2022, 27, e350-e352.	3.7	4
8	Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. <i>Cancer Treatment Reviews</i> , 2022, 103, 102333.	7.7	21
9	Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. <i>Cancers</i> , 2022, 14, 955.	3.7	9
10	The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients. <i>Current Oncology Reports</i> , 2022, 24, 861-874.	4.0	10
11	Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 829553.	2.4	11
12	Fatal myositis and myasthenia induced by atezolizumab for the treatment of hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101854.	1.5	3
13	Mitigation and management strategies for ocular events associated with tisotumab vedotin. <i>Gynecologic Oncology</i> , 2022, 165, 385-392.	1.4	20
14	Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration. <i>ESC Heart Failure</i> , 2022, , .	3.1	4
15	Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 213.	6.3	18
16	Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. <i>Vaccines</i> , 2022, 10, 540.	4.4	8
17	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. <i>Diagnostics</i> , 2022, 12, 685.	2.6	1
18	Optimizing the prescription doses and tolerability of systemic therapy in head and neck cancer patients. <i>Current Opinion in Oncology</i> , 2022, Publish Ahead of Print, .	2.4	0

#	ARTICLE	IF	CITATIONS
19	Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review. <i>Journal of Imaging</i> , 2022, 8, 99.	3.0	4
20	Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 683-694.	3.7	45
21	Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword. <i>Cancers</i> , 2022, 14, 2060.	3.7	7
22	Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews. <i>Drugs</i> , 2022, , .	10.9	3
23	Ominous Electrocardiographic Abnormalities in a Patient With Hepatocellular Carcinoma. <i>JAMA Internal Medicine</i> , 2022, , .	5.1	2
25	Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 565-574.	2.4	1
26	American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach. <i>Endocrine Practice</i> , 2022, 28, 719-731.	2.1	12
29	Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	0
30	Neurotoxicity as a Rare side effect of immune checkpoint inhibitors. A case report and review of the literature. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.5	1
31	Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders. <i>Current Problems in Cancer</i> , 2022, 46, 100864.	2.0	3
32	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. <i>Cancers</i> , 2022, 14, 2293.	3.7	4
33	Toxic Myopathies. <i>Current Treatment Options in Neurology</i> , 0, , 1.	1.8	1
34	Immune Checkpoint Inhibitors for the Treatment of Gestational Trophoblastic Neoplasia: Rationale, Effectiveness, and Future Fertility. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1035-1043.	3.0	6
35	Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2896-2908.e4.	0.7	9
36	Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives. <i>Journal of Inflammation Research</i> , 0, Volume 15, 3105-3118.	3.5	6
37	Immune Related Adverse Events of the Thyroid – A Narrative Review. <i>Frontiers in Endocrinology</i> , 2022, 13, .	3.5	19
38	Cutaneous metastasis of PD-L1 positive cervical carcinoma. <i>Gynecologic Oncology Reports</i> , 2022, 41, 101003.	0.6	2
39	Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade. <i>European Thyroid Journal</i> , 2022, 11, .	2.4	2

#	ARTICLE	IF	CITATIONS
40	Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2022, 187, 381-391.	1.5	14
41	Immunotherapy toxicities: An SGO clinical practice statement. <i>Gynecologic Oncology</i> , 2022, , .	1.4	1
42	Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	7
43	Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. <i>Immunotherapy Advances</i> , 2022, 2, .	3.0	15
44	Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. , 2022, 10, e004762.		19
45	Thrombocytopaenia as an immune-related adverse event in malignant pleural mesothelioma: a case report. <i>JTO Clinical and Research Reports</i> , 2022, , 100351.	1.1	0
46	Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	9
47	The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3107-e3114.	3.6	7
48	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	3.8	29
49	Role of cardiac <scp>MRI</scp> in the diagnosis of immune checkpoint inhibitor-associated myocarditis. <i>International Journal of Cancer</i> , 2022, 151, 1860-1873.	5.1	19
50	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. <i>American Journal of Clinical Dermatology</i> , 0, , .	6.7	3
51	Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	9
52	Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group. <i>Clinical and Translational Oncology</i> , 2022, 24, 2010-2020.	2.4	8
53	Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	6
54	Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.		21
55	Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
57	SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGF β 2, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study. <i>Clinical Cancer Research</i> , 2022, 28, 5297-5305.	7.0	20
58	Durable complete remission after Pembrolizumab in pretreated advanced endometrial cancer: A case report. <i>Current Problems in Cancer Case Reports</i> , 2022, 7, 100172.	0.1	0

#	ARTICLE	IF	CITATIONS
59	ICIs-Related Cardiotoxicity in Different Types of Cancer. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 203.	1.6	11
60	(Immune Checkpoint Inhibitor Myocarditis: Current Views on Diagnosis and Treatment). <i>Cor Et Vasa</i> , 2022, 64, 310-315.	0.1	0
61	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	16
62	Hypophysitis. <i>Endocrine Practice</i> , 2022, 28, 901-910.	2.1	3
63	Non-small cell lung cancer in the era of immunotherapy. <i>Seminars in Oncology</i> , 2022, 49, 337-343.	2.2	1
64	The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 800-807.e1.	4.9	5
65	The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression. <i>Cureus</i> , 2022, , .	0.5	0
66	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	2.4	6
67	Experimental investigation of skin toxicity after immune checkpoint inhibition in combination with radiation therapy. <i>Journal of Pathology</i> , 2022, 258, 189-198.	4.5	1
68	Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
69	Therapy for Stage IV Non-“Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 3323-3343.	1.6	63
71	TNF-± Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	11
72	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	17.0	58
73	Venous and arterial thromboembolism with immunotherapy compared to platinum-based therapy. <i>Thrombosis Research</i> , 2022, 217, 48-51.	1.7	1
74	Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system. <i>International Immunopharmacology</i> , 2022, 110, 109015.	3.8	4
75	Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-“A Retrospective, Monocentric Study. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
76	Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis). <i>Current Opinion in Gastroenterology</i> , 2022, 38, 516-520.	2.3	8
77	Recognising immunotherapy-induced meningoencephalitis: a case during treatment for primary metastatic melanoma of the bladder neck. <i>BMJ Case Reports</i> , 2022, 15, e249411.	0.5	1

#	ARTICLE	IF	CITATIONS
79	Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system. <i>Haemophilia</i> , 2022, 28, .	2.1	4
80	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. , 2022, 10, e004434.		14
81	Severe infections in recipients of cancer immunotherapy: what intensivists need to know. <i>Current Opinion in Critical Care</i> , 2022, 28, 540-550.	3.2	5
82	Distinct immune-effector and metabolic profile of CD8 ⁺ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1730-1741.	0.9	12
83	Immunotherapy Recall: Chemoradiation-Induced Reactivation of Immune Checkpoint Inhibitor Nephritis. <i>JCO Precision Oncology</i> , 2022, , .	3.0	0
84	Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis. <i>Diagnostics</i> , 2022, 12, 1961.	2.6	7
85	Adverse Renal Effects of Anticancer Immunotherapy: A Review. <i>Cancers</i> , 2022, 14, 4086.	3.7	3
86	AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. <i>Hepatology</i> , 2023, 77, 1036-1065.	7.3	41
87	A Challenging Case of Eyelid Ptosis and Diplopia Induced by Pembrolizumab. <i>Cureus</i> , 2022, , .	0.5	0
88	The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	16
89	Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation. <i>Anticancer Research</i> , 2022, 42, 4589-4595.	1.1	1
90	Immune checkpoint Inhibitor-induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 109, 102440.	7.7	28
91	Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113618.	5.6	11
92	Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. <i>European Journal of Cancer</i> , 2022, 175, 224-235.	2.8	13
93	Nervous System Related Adverse Reactions and Management Strategies of Tumor Immune Checkpoint Inhibitors. <i>Advances in Clinical Medicine</i> , 2022, 12, 7964-7971.	0.0	0
94	Evaluation and Management of Acute High-Grade Immunotherapy-Related Neurotoxicity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
95	Arthritis Associated with Immune Checkpoint Inhibitors. <i>Rare Diseases of the Immune System</i> , 2022, , 231-242.	0.1	0
96	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. <i>Diagnostics</i> , 2022, 12, 2091.	2.6	5

#	ARTICLE	IF	CITATIONS
97	Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report. <i>Clinical Lung Cancer</i> , 2022, 23, e563-e567.	2.6	2
98	Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2022, 11, 1555-1566.	2.8	8
99	Cardiovascular complications of immune checkpoint inhibitors for cancer. <i>European Heart Journal</i> , 2022, 43, 4458-4468.	2.2	30
100	Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. <i>Journal of Thoracic Oncology</i> , 2023, 18, 79-92.	1.1	11
101	Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature. <i>Diagnostics</i> , 2022, 12, 2116.	2.6	1
102	Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-10.	2.4	0
103	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
104	Therapeutic plasma exchange in the management of immune checkpoint inhibitor-associated immune-related adverse effects: A review. <i>Transfusion</i> , 2022, 62, 2370-2390.	1.6	1
105	Immunotherapy-Associated Uveitis. , 0, , .		0
106	Phase 1 trial of CV301 in combination with anti-EPD therapy in nonsquamous non-small cell lung cancer. <i>International Journal of Cancer</i> , 0, , .	5.1	1
107	Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1370-1382.	3.7	8
108	COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. , 2022, 10, e005111.		17
109	Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 877-883.	2.5	3
110	Myocarditis Induced by Immunotherapy in Metastatic Melanoma: Review of Literature and Current Guidelines. <i>Journal of Clinical Medicine</i> , 2022, 11, 5182.	2.4	2
111	Application of artificial liver in immune-related liver injury induced by immune checkpoint inhibitor: Case reports and review of the literature. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
112	Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4369.	3.7	4
113	Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
114	Checking Out the Associations Between Inflammatory Bowel Disease and Checkpoint Inhibitor Colitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5010-5013.	2.3	1

#	ARTICLE	IF	CITATIONS
115	Which cardiac parameters best predict the cardiovascular outcomes among patients with anti-PD-1 immunotherapy-induced myocardial injury?. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1
116	Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review. , 2022, 000, 000-000.		1
117	Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30151.	1.0	0
118	Drug-related immune-mediated myelopathies. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	1
119	Infliximab in the treatment of tislelizumab-induced steroid-refractory immune checkpoint inhibitor-related pneumonia: case report and literature review. <i>Translational Cancer Research</i> , 2022, 11, 3309-3314.	1.0	3
120	Imaging Effector Memory T-Cells Predicts Response to PD1-Chemotherapy Combinations in Colon Cancer. <i>Biomedicines</i> , 2022, 10, 2343.	3.2	1
121	Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2022, 18, 794-805.	9.6	20
122	Research focus and theme trend on fulminant myocarditis: A bibliometric analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1
123	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 641-656.	8.0	37
124	Situations urgentes en médecine interne. <i>Revue De Medecine Interne</i> , 2022, 43, 43/10S38-43/10S40.	1.0	0
125	Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	5
126	Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life. <i>European Journal of Cancer</i> , 2022, 176, 88-99.	2.8	18
127	Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103826.	4.4	6
128	Immune Checkpoint Inhibitors in Gastroesophageal Junction or Gastric Cancer. , 2022, , 1-25.		0
129	A case of crescentic glomerulonephritis and acute tubulointerstitial nephritis requiring temporary hemodialysis during nivolumab treatment for renal cell carcinoma. <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 595-601.	0.1	0
130	Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7
131	Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study. <i>Acta Oncologica</i> , 2022, 61, 1339-1346.	1.8	1
133	Update on Immune Checkpoint Inhibitor Enterocolitis. <i>Current Gastroenterology Reports</i> , 2022, 24, 171-181.	2.5	5

#	ARTICLE	IF	CITATIONS
134	Imaging Memory T-Cells Stratifies Response to Adjuvant Metformin Combined with \hat{I} PD-1 Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12892.	4.1	1
135	Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management. <i>Journal of Clinical Medicine</i> , 2022, 11, 5977.	2.4	2
136	Pyrogenic lower limbs. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 719-720.	0.9	0
137	Immune-Mediated Pneumonitis: A Clinical Conundrum in a Patient with Stage IV Lung Adenocarcinoma with a Dramatic and Durable Response to Checkpoint Inhibitor Case Report. <i>Current Problems in Cancer Case Reports</i> , 2022, , 100195.	0.1	0
138	Clinical cancer immunotherapy: Current progress and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	39
139	Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non- \hat{C} Small-Cell Lung Cancer in CheckMate 227. <i>Journal of Clinical Oncology</i> , 2023, 41, 1200-1212.	1.6	75
140	Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. <i>JAMA Oncology</i> , 2022, 8, 1794.	7.1	33
141	LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials. <i>Cancers</i> , 2022, 14, 4975.	3.7	9
142	Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients. <i>Current Oncology</i> , 2022, 29, 7953-7963.	2.2	10
143	Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists \hat{C} ™ Perspective. <i>Journal of Clinical Medicine</i> , 2022, 11, 6021.	2.4	2
144	Immunotherapy and Modern Radiotherapy Technique for Older Patients with Locally Advanced Head and Neck Cancer: A Proposed Paradigm by the International Geriatric Radiotherapy Group. <i>Cancers</i> , 2022, 14, 5285.	3.7	2
145	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. <i>Cancers</i> , 2022, 14, 5403.	3.7	7
146	A Novel Potential Role for Monocytes Revealed by Single Cell Analysis of Immunotherapy Induced Immune Related Adverse Events. <i>Cancers</i> , 2022, 14, 5407.	3.7	2
147	Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study. <i>PLoS ONE</i> , 2022, 17, e0275865.	2.5	4
148	To treat or not to treat: PD-L1 inhibitor-induced keratoacanthoma and squamous cell carcinoma. <i>Archives of Dermatological Research</i> , 2023, 315, 903-915.	1.9	2
149	Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report. <i>Cureus</i> , 2022, , .	0.5	3
150	Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	14
151	Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors. <i>Respiratory Medicine and Research</i> , 2022, 82, 100969.	0.6	3

#	ARTICLE	IF	CITATIONS
152	Case 5: A 41-Year-Old Woman With Palpitation. <i>Journal of Korean Medical Science</i> , 2022, 37, .	2.5	0
153	Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. <i>Chemical Society Reviews</i> , 2023, 52, 47-96.	38.1	19
154	Oncologic Emergencies: Pathophysiology, Diagnosis, and Initial Management. , 2022, , .		0
155	An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis. , 2023, , 157-184.		0
156	Immunotherapy and Endocrine Oncology. , 2022, , 1-36.		0
157	Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report. <i>Translational Lung Cancer Research</i> , 2022, 11, 2346-2355.	2.8	0
158	Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?. <i>Renal Failure</i> , 2022, 44, 2058-2067.	2.1	1
159	Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
160	Check this out: treatment paradigms in immune-checkpoint inhibitor colitis. <i>Current Opinion in Gastroenterology</i> , 2023, 39, 43-49.	2.3	1
161	Bullous pemphigoid associated with anti- $\text{CD}137$ programmed cell death protein 1 and $\text{CD}137$ cell death ligand 1 therapy: A case series of 13 patients. <i>Australasian Journal of Dermatology</i> , 0, , .	0.7	4
162	Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
163	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	4.0	25
164	Reliability and validity of the simplified Chinese version of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator. <i>Quality of Life Research</i> , 0, , .	3.1	1
165	Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	3.3	8
166	IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma. <i>Nature Medicine</i> , 2022, 28, 2592-2600.	30.7	22
167	Multiple White Plaques in the Esophagus: A Possible Case of Esophageal Mucosal Alteration Associated With Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Cureus</i> , 2022, , .	0.5	1
168	Treatment of rheumatic adverse events of cancer immunotherapy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101805.	3.3	9
169	Neurological Complications of Conventional and Novel Anticancer Treatments. <i>Cancers</i> , 2022, 14, 6088.	3.7	9

#	ARTICLE	IF	CITATIONS
170	Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1514-1525.	3.6	8
171	Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>JACC: CardioOncology</i> , 2022, 4, 689-700.	4.0	19
173	Acute Kidney Injury in Cancer Immunotherapy Recipients. <i>Cells</i> , 2022, 11, 3991.	4.1	4
174	Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment. <i>BMJ Case Reports</i> , 2022, 15, e251966.	0.5	4
175	A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?. <i>JACC: CardioOncology</i> , 2022, 4, 670-672.	4.0	1
176	Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions. <i>JACC: CardioOncology</i> , 2022, 4, 704-707.	4.0	12
177	Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support. <i>JACC: CardioOncology</i> , 2022, 4, 722-726.	4.0	3
178	Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2023, 41, 1470-1491.	1.6	46
179	Role of Immunotherapy in Breast Cancer. <i>JCO Oncology Practice</i> , 2023, 19, 167-179.	2.9	19
180	Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy. <i>Acta Oncologica</i> , 2023, 62, 62-69.	1.8	5
181	Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
182	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	13
183	Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. <i>Cancers</i> , 2023, 15, 375.	3.7	10
184	Distinct T cell sub-clusters may serve as biomarkers for immune related adverse events. <i>Cell Reports Medicine</i> , 2023, 4, 100902.	6.5	0
185	Squamous Cell Carcinoma of Head and Neck. , 0, , .		0
186	A brief review of renal-limited thrombotic microangiopathy associated with immune checkpoint inhibitors. <i>Journal of Onco-Nephrology</i> , 0, , 239936932211477.	0.6	1
187	Microbiome influencers of checkpoint blockade-associated toxicity. <i>Journal of Experimental Medicine</i> , 2023, 220, .	8.5	13
189	Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. <i>Immunotherapy</i> , 2023, 15, 85-91.	2.0	3

#	ARTICLE	IF	CITATIONS
190	The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
191	Checkpoint inhibitor hepatotoxicity: pathogenesis and management. <i>Hepatology</i> , 2024, 79, 198-212.	7.3	2
192	Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. <i>Journal of Clinical Oncology</i> , 2023, 41, 1943-1948.	1.6	19
193	Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. <i>Hepatology Research</i> , 2023, 53, 450-459.	3.4	2
194	Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
195	The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
196	Corticosteroids and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 2580-2587.	7.0	8
197	The development of a t<scp>umor-associated</scp> autoantibodies panel to predict clinical outcomes for immune checkpoint i<scp>nhibitor-based</scp> treatment in patients with advanced n<scp>on-small</scp>-cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 497-505.	1.9	1
198	T follicular helper cells in cancer. <i>Trends in Cancer</i> , 2023, 9, 309-325.	7.4	40
199	Crescentic Fibrillary Glomerulonephritis in the Setting of Immune Checkpoint Inhibitor Therapy: A Report of Two Cases. <i>Glomerular Diseases</i> , 2023, 3, 69-74.	1.0	1
200	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. <i>Clinics and Practice</i> , 2023, 13, 22-40.	1.4	14
201	Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000989.	2.7	10
202	Immune checkpoint blockade PD-1 therapy for primary liver cancer: incidence and influencing factors of thyroid dysfunction. <i>Infectious Agents and Cancer</i> , 2022, 17, .	2.6	1
203	Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series. <i>Journal of Clinical Medicine</i> , 2023, 12, 130.	2.4	4
204	Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings. <i>Radiologia Medica</i> , 2023, 128, 212-221.	7.7	2
205	Pulmonary Side Effects of Immunotherapy. , 2023, , 1-13.		0
207	Melanoma with Brain Metastasis. , 2023, , 1-30.		0
208	Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of Pembrolizumab Treatment. <i>Journal of Voice</i> , 2023, , .	1.5	1

#	ARTICLE	IF	CITATIONS
209	Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 939-951.	2.9	5
211	Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers—Emerging Strategies for Clinical Management. <i>Transplantation</i> , 2023, 107, 1452-1462.	1.0	7
212	Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review. <i>Seminars in Oncology</i> , 2022, 49, 439-455.	2.2	3
213	Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know. <i>Praxis</i> , 2023, 112, 160-171.	0.4	1
214	Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events. <i>Journal of Cancer Education</i> , 0, , .	1.3	0
215	Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis. <i>Current Oncology Reports</i> , 2023, 25, 743-751.	4.0	2
216	Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer. <i>Immunotherapy</i> , 2023, 15, 397-400.	2.0	1
217	Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	2
218	Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center. <i>Immunotherapy</i> , 2023, 15, 417-428.	2.0	0
219	Accelerating the Evolution of Immune-Related Enterocolitis Management. <i>Journal of Clinical Oncology</i> , 2023, 41, 3110-3115.	1.6	2
220	Drug-Induced Interstitial Lung Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2023, 43, 341-357.	1.9	9
221	Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis — The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging. <i>Neoplasia</i> , 2023, 39, 100892.	5.3	1
222	Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort study. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 1215-1218.	1.2	1
223	Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. <i>International Immunopharmacology</i> , 2023, 119, 110158.	3.8	2
224	Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology. <i>Seminars in Immunology</i> , 2023, 67, 101754.	5.6	4
225	Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report. <i>Gynecologic Oncology Reports</i> , 2023, 47, 101174.	0.6	1
226	Thyroid and Aging. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 229-243.	3.2	3
227	Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents. <i>Revue Neurologique</i> , 2023, 179, 405-416.	1.5	0

#	ARTICLE	IF	CITATIONS
228	Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103923.	4.4	1
229	Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	8
230	Dearth of ICD Codes for Complications of Immune Checkpoint Inhibitors Impedes Clinical Care and Research. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.2	0
231	Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2023, 46, 94-100.	1.3	1
232	A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry. <i>Cureus</i> , 2023, , .	0.5	0
233	Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss. <i>Liver Transplantation</i> , 2023, 29, 598-606.	2.4	6
234	Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	11
235	Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. <i>Hepatology International</i> , 2023, 17, 709-719.	4.2	17
236	Combination therapy with immune check point inhibitors and acute kidney injury. <i>Acta OncolÃ³gica</i> , 2023, 62, 121-125.	1.8	2
237	Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature. <i>ESMO Open</i> , 2023, 8, 100791.	4.5	3
238	Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. <i>Heliyon</i> , 2023, 9, e13725.	3.2	0
239	Immunotherapy associated central nervous system complications in primary brain tumors. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
240	Peripheral nervous system adverse events associated with immune checkpoint inhibitors. <i>Journal of Neurology</i> , 2023, 270, 2975-2986.	3.6	3
241	Pembrolizumab-Induced Acral Vasculitis. <i>Journal of Immunotherapy</i> , 2023, 46, 107-110.	2.4	1
242	Advances in immune checkpoint inhibitors induced-cardiotoxicity. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
243	A Study Design to Harmonize Patient-Reported Outcomes Across Data Sets. <i>JCO Clinical Cancer Informatics</i> , 2023, , .	2.1	0
244	Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. <i>Cancer Discovery</i> , 2023, 13, 1100-1115.	9.4	40
245	The need for kidney biopsy in the management of side effects of target and immunotherapy. , 0, 3, .		0

#	ARTICLE	IF	CITATIONS
246	Immune-related adverse events as potential surrogates of immune checkpoint inhibitorsâ€™ efficacy: a systematic review and meta-analysis of randomized studies. <i>ESMO Open</i> , 2023, 8, 100787.	4.5	13
247	Successful treatment of immune-related lichenoid dermatitis by Weiling decoction in a patient with non-small cell lung cancer: A case report and review of literature. <i>Explore: the Journal of Science and Healing</i> , 2023, 19, 730-735.	1.0	3
248	The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2088-2099.	4.4	11
249	Immunotherapy and Gastrointestinal Toxicities. <i>Praxis</i> , 2023, 112, 172-177.	0.4	1
250	Side Effects of Cancer Immunotherapies: Dermatologic and Rheumatologic Toxicities. <i>Praxis</i> , 2023, 112, 184-188.	0.4	1
251	Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 1568.	3.7	2
252	Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2217-2231.	4.2	2
253	Steroid-dependent pericarditis following anti-PD1 immunotherapy in a metastatic melanoma patient: a case report. <i>European Heart Journal - Case Reports</i> , 2023, 7, .	0.6	1
255	Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer. <i>Scientific Reports</i> , 2023, 13, .	3.3	2
256	Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. <i>Cancers</i> , 2023, 15, 1629.	3.7	9
257	Blocking soluble TNF α sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. , 2023, 11, e005325.		6
258	Nivolumabâ€induced acute tubular injury: A case report. <i>Clinical Case Reports (discontinued)</i> , 2023, 11, .	0.5	1
259	Rheumatologic immune checkpoint inhibitor-related adverse events. <i>Current Opinion in Rheumatology</i> , 2023, 35, 141-148.	4.3	2
260	Immune Checkpoint Inhibitorâ€Associated Sarcoidosis Reaction in the Kidney: Case Report. <i>Kidney Medicine</i> , 2023, 5, 100626.	2.0	4
261	Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review. <i>Oncology and Therapy</i> , 0, , .	2.6	0
262	Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. , 2023, 11, e005841.		12
263	Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management. <i>Revue Neurologique</i> , 2023, 179, 506-515.	1.5	5
264	Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. <i>Biology</i> , 2023, 12, 472.	2.8	2

#	ARTICLE	IF	CITATIONS
265	Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	2
266	Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine. <i>Cancers</i> , 2023, 15, 1891.	3.7	2
267	Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti- PD-1 therapy. <i>Cancer Medicine</i> , 2023, 12, 11334-11343.	2.8	1
268	The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study. <i>Cancer</i> , 2023, 129, 1885-1894.	4.1	2
269	Drug-induced liver injury. <i>Medicine</i> , 2023, 51, 342-346.	0.4	2
270	Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology. <i>Genes and Diseases</i> , 2024, 11, 807-818.	3.4	4
271	Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
272	Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases. <i>Diagnostics</i> , 2023, 13, 1243.	2.6	9
273	ComplicaÅii mediate imunologic ale anticorpilor monoclonali folosiÅi Å®n oncohematologie. <i>Oncolog-Hematolog Ro</i> , 2023, 1, 26.	0.0	0
274	Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.9	4
277	Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab. <i>BMJ Case Reports</i> , 2023, 16, e253696.	0.5	2
278	Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors. <i>Clinical and Experimental Medicine</i> , 2023, 23, 3907-3918.	3.6	5
279	Successful treatment of immune-related cystitis with bladder hydrodistension. <i>IJU Case Reports</i> , 0, , .	0.3	0
280	Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma: A multicenter real-world experience in Israel. <i>Cancer Medicine</i> , 2023, 12, 12065-12070.	2.8	5
281	Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	1
282	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. <i>Journal of Clinical Apheresis</i> , 2023, 38, 77-278.	1.3	81
283	Endocrine Dysfunction From Immune Checkpoint Inhibitors: Pearls and Pitfalls in Evaluation and Management. <i>JCO Oncology Practice</i> , 0, , .	2.9	2
284	Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group. <i>Clinical and Translational Oncology</i> , 0, , .	2.4	0

#	ARTICLE	IF	CITATIONS
285	Clinical guideline highlights for the hospitalist: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. <i>Journal of Hospital Medicine</i> , 2023, 18, 1013-1016.	1.4	1
286	Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist. <i>Cancer Treatment Reviews</i> , 2023, 116, 102559.	7.7	1
287	Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report. <i>Medicine (United States)</i> , 2023, 102, e33550.	1.0	1
288	A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7630.	4.1	1
289	A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy. <i>Cancers</i> , 2023, 15, 2506.	3.7	4
290	The Evolving Etiologic and Epidemiologic Portrait of Pericardial Disease. <i>Canadian Journal of Cardiology</i> , 2023, 39, 1047-1058.	1.7	1
291	Gilteritinib-induced severe immune-related enteritis: a possible case report. <i>Anti-Cancer Drugs</i> , 2023, 34, 896-900.	1.4	1
293	Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2023, 12, 12861-12873.	2.8	1
296	Immunotherapy and Cancer: The Pharmacists'™ Perspective. , 2023, , 1-34.		0
297	Pembrolizumab-induced optic neuropathy – a case report. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
298	Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes. <i>International Journal of Clinical Oncology</i> , 2023, 28, 860-871.	2.2	2
299	Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	12
300	Checkpoint inhibitor-induced gastritis followed by delayed severe hepatitis in a patient with lung metastases of head and neck squamous cell carcinoma: a case report. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
301	Uncovering the Burden of Immune-Related Adverse Events in Immunotherapy: Insights from a Nationally Representative Sample. <i>Targeted Oncology</i> , 2023, 18, 451-461.	3.6	0
302	Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2023, 29, 248-255.	2.6	1
303	PD-1-based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta-analysis focus on PD-1 expression level. <i>Cancer Reports</i> , 0, , .	1.4	2
304	Toxicité des immunothérapies anti-cancer. <i>Medecine/Sciences</i> , 2023, 39, 445-451.	0.2	0
305	Checkpoint Inhibitor-Induced Colitis: An Update. <i>Biomedicines</i> , 2023, 11, 1496.	3.2	5

#	ARTICLE	IF	CITATIONS
306	The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review. JCO Clinical Cancer Informatics, 2023, , .	2.1	1
307	Immune-related adverse events of immune checkpoint inhibitors: a review. Frontiers in Immunology, 0, 14, .	4.8	18
308	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
310	Advances in systemic therapies for triple negative breast cancer. BMJ, The, 0, , e071674.	6.0	17
311	Calprotectin in Patients with Rheumatic Immunomediated Adverse Effects Induced by Checkpoints Inhibitors. Cancers, 2023, 15, 2984.	3.7	1
312	Renal Immune-related Adverse Event of Pembrolizumab Masked by Pemetrexed. Internal Medicine, 2024, 63, 265-270.	0.7	1
313	Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	8.6	1
314	Updates in toxicities associated with immune checkpoint inhibitors. Expert Review of Clinical Immunology, 2023, 19, 1117-1129.	3.0	1
315	Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence. Cureus, 2023, , .	0.5	0
316	Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology. Cancers, 2023, 15, 3055.	3.7	3
318	Atezolizumab-associated myositis in a patient with unresectable hepatocellular carcinoma. Journal of Oncology Pharmacy Practice, 2023, 29, 1757-1761.	0.9	2
319	Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis. , 2023, 11, e006982.		1
320	Part <sc>II</sc>: Interactive case: <sc>Drug-induced</sc> endocrine disorders. JACCP Journal of the American College of Clinical Pharmacy, 2023, 6, 663-668.	1.0	0
321	T cell immunity in interstitial lung disease with non-small cell lung cancer patients. Lung Cancer, 2023, 182, 107278.	2.0	0
322	Generation of novel complete HLA class I monoallelic cell lines used in an MHC stabilization assay for neoantigen evaluation. Oncology Letters, 2023, 26, .	1.8	0
323	Tolerability of immune checkpoint inhibitors in patients with cancer and pre-existing multiple sclerosis. European Journal of Cancer, 2023, 189, 112928.	2.8	2
325	Atezolizumab-induced cerebellar ataxia in a patient with metastatic small cell lung cancer: A case report and literature review. Journal of Oncology Pharmacy Practice, 2024, 30, 201-205.	0.9	1
327	Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. , 2023, 11, e006814.		8

#	ARTICLE	IF	CITATIONS
328	Immune checkpoint inhibitor induced neurocognitive deficits in patients. <i>Brain Communications</i> , 2023, 5, .	3.3	1
329	The Role of Abdominal Surgery in Refractory Immune Checkpoint Inhibitor Enterocolitis: A Case Report. <i>Case Reports in Oncology</i> , 0, , 453-460.	0.7	1
330	An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
331	Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2023, , .	3.8	6
332	Lessons from the diagnosis and treatment of severe immune checkpoint inhibitor-associated pneumonia: a case report. <i>Immunotherapy</i> , 2023, 15, 897-903.	2.0	1
333	Neurologic Complications of Cancer Immunotherapy. <i>Current Oncology</i> , 2023, 30, 5876-5897.	2.2	0
334	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. <i>Drug Safety</i> , 2023, 46, 819-833.	3.2	2
335	Toxicity Management of Systemic Kidney Cancer Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2023, , .	2.2	0
336	Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality. <i>European Journal of Neurology</i> , 2023, 30, 3221-3227.	3.3	3
337	Immune checkpoint inhibitor-related adverse events: Real-world experience from a single veterans affairs medical center. <i>Journal of Oncology Pharmacy Practice</i> , 0, , .	0.9	0
338	Cancer treatment-related cardiotoxicity: a focus on sacubitril/valsartan. <i>Cardiology Plus</i> , 0, Publish Ahead of Print, .	0.7	0
339	Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2023, , .	3.0	4
340	Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition. <i>Current Oncology</i> , 2023, 30, 4527-4537.	2.2	0
341	Immune mechanisms of toxicity from checkpoint inhibitors. <i>Trends in Cancer</i> , 2023, 9, 543-553.	7.4	17
342	Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2023, 15, 2538.	3.7	4
343	Update on Immune Checkpoint Inhibitor-Associated Uveitis. <i>Current Ophthalmology Reports</i> , 0, , .	1.2	0
345	A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2023, , .	3.8	0
346	Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 1243-1255.	1.2	1

#	ARTICLE	IF	CITATIONS
347	Checking immunotoxicity risks of checkpoint blockade. <i>Nature Cancer</i> , 2023, 4, 779-780.	13.2	1
348	Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	5
349	Analyzing fulminant myocarditis research trends and characteristics using the follower-leading clustering algorithm (FLCA): A bibliometric study. <i>Medicine (United States)</i> , 2023, 102, e34169.	1.0	7
350	Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature. <i>Immunotherapy</i> , 2023, 15, 1125-1132.	2.0	3
352	Seronegative Rheumatoid Arthritis Secondary to Immune Checkpoint Inhibitor in a Renal Cell Carcinoma Patient Encountered in a Rural Community-Based Rheumatology Clinic: A Case Report. <i>Cureus</i> , 2023, , .	0.5	0
353	Checkpoint Inhibitor-Induced Pneumonitis: Incidence and Management. <i>Current Pulmonology Reports</i> , 0, , .	1.3	0
354	A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report. <i>Current Problems in Cancer Case Reports</i> , 2023, 11, 100252.	0.1	0
355	Managing Adverse Effects of Novel Therapeutic Agents in Gynecologic Malignancies. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.6	0
356	A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
357	An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic. <i>Immunotherapy</i> , 2023, 15, 921-932.	2.0	1
358	Pegloticase in Uncontrolled Gout. <i>Journal of Infusion Nursing</i> , 2023, 46, 223-231.	2.3	0
359	Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study. <i>Journal of Gastroenterology</i> , 2023, 58, 1043-1054.	5.1	5
360	Editorial: Assessment and management of adverse drug reactions in oncology. <i>Frontiers in Allergy</i> , 0, 4, .	2.8	0
361	Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. <i>International Journal of Clinical Oncology</i> , 2023, 28, 1315-1332.	2.2	4
362	Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11504.	4.1	3
363	Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity. <i>Current Oncology</i> , 2023, 30, 6862-6871.	2.2	2
364	Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2024, 13, 89-98.	7.7	0
365	Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 720-725.	0.8	2

#	ARTICLE	IF	CITATIONS
366	Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2023, 31, .	2.2	2
367	CACA guidelines for holistic integrative management of nasopharyngeal carcinoma. , 2023, 2, .		0
368	Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
369	Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis. <i>Expert Review of Clinical Pharmacology</i> , 0, , 1-9.	3.1	0
370	Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case report. <i>Respiratory Medicine Case Reports</i> , 2023, 45, 101898.	0.4	0
372	Rituximab in steroid-refractory immune-related pancreatitis: a case report. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
373	Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. , 2023, 11, e006500.		6
374	Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?. <i>Current Treatment Options in Oncology</i> , 0, , .	3.0	1
375	Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
376	Immune-related acute kidney injury in Australian non-small cell lung cancer patients: Real-world results. <i>Lung Cancer</i> , 2023, 184, 107325.	2.0	1
377	Immune Checkpoint Inhibitor-Induced Hemorrhagic Gastritis. <i>ACG Case Reports Journal</i> , 2023, 10, e01128.	0.4	1
378	Systemic Therapy for Melanoma: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2023, 41, 4794-4820.	1.6	15
379	Chemoimmunotherapy for esophageal squamous cell carcinomaâ€”Summary and discussion of recent clinical trials. , 2023, 2, .		0
380	Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications. <i>Current Oncology</i> , 2023, 30, 7638-7653.	2.2	0
381	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	5
383	Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: Moving beyond â€œmaculopapular rashâ€œ. <i>Immunological Reviews</i> , 2023, 318, 22-36.	6.0	2
384	Immune checkpoint inhibitors induced side effects of the peripheral nervous system. <i>Current Opinion in Neurology</i> , 0, , .	3.6	0
385	Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	0

#	ARTICLE	IF	CITATIONS
386	Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer. <i>Lung Cancer</i> , 2023, 184, 107350.	2.0	1
387	Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 909-919.	2.4	1
388	Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial. <i>JMIR Research Protocols</i> , 0, 12, e48386.	1.0	0
389	Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma. <i>Neurology</i> , 2023, 101, .	1.1	1
390	Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis. <i>Current Oncology</i> , 2023, 30, 8117-8133.	2.2	1
391	Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review. <i>International Journal of Urology</i> , 2023, 30, 1068-1077.	1.0	0
392	Trial Design for Cancer Immunotherapy: A Methodological Toolkit. <i>Cancers</i> , 2023, 15, 4669.	3.7	0
393	Varying presentations of immune checkpoint inhibitor-associated myocarditis: A case report of the clinical characteristics and outcomes of three patients. <i>Gynecologic Oncology Reports</i> , 2023, 49, 101271.	0.6	0
394	Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events. , 2023, 11, e007557.		1
395	Effects of immune-related adverse events (<scp>irAEs</scp>) and their treatment on antitumor immune responses. <i>Immunological Reviews</i> , 2023, 318, 167-178.	6.0	7
396	Coexistence of Anti-PD1-Induced Immune Myocarditis and Complete Atrioventricular Block: A Case Report. <i>American Journal of Cardiology</i> , 2023, 207, 35-38.	1.6	0
397	Immune checkpoint inhibitor-associated myocarditis: a systematic analysis of case reports. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
398	Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status. <i>Cancer Management and Research</i> , 0, Volume 15, 913-927.	1.9	0
399	Non-cellular immunotherapies in pediatric central nervous system tumors. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
400	Immune signatures of checkpoint inhibitor-induced autoimmunity - a focus on neurotoxicity. <i>Neuro-Oncology</i> , 0, , .	1.2	0
401	Guidelines in Cardio-Oncology: The Balance Between Evidence and Expert Opinion. <i>Current Treatment Options in Cardiovascular Medicine</i> , 0, , .	0.9	0
402	Immune-Related Adverse Events in Patients with Lung Cancer. <i>Current Oncology Reports</i> , 0, , .	4.0	0
403	HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors. <i>Scientific Reports</i> , 2023, 13, .	3.3	5

#	ARTICLE	IF	CITATIONS
404	Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. <i>Supportive Care in Cancer</i> , 2023, 31, .	2.2	0
405	Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review. <i>Critical Pathways in Cardiology</i> , 2023, 22, 69-82.	0.5	1
406	Immunotherapy in Melanoma: Recent Advancements and Future Directions. <i>Cancers</i> , 2023, 15, 4176.	3.7	1
407	Late-Onset Hemorrhagic Pericardial Effusion and Cardiac Tamponade Associated With Immune Checkpoint Inhibitors: Case Report and Literature Review. <i>Cureus</i> , 2023, , .	0.5	1
408	Decisional conflict and its determinants among patients with cancer undergoing immunotherapy combined with chemotherapy or targeted therapy: a cross-sectional study. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
409	Combination immune checkpoint therapy carried on despite grade 4 immune-related hepatotoxicity during treatment of metastatic melanoma: Case report and review of literature. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102192.	1.5	1
410	Soluble galectinâ€³ as a microenvironmentâ€relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. <i>Molecular Oncology</i> , 2024, 18, 190-215.	4.6	2
411	Organizational Impact of Immunotherapies in Advanced Cancers in France. <i>JCO Global Oncology</i> , 2023, , .	1.8	0
412	T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. , 2023, 11, e007236.		3
413	<i>Faecalibacterium prausnitzii</i> Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade. <i>Cancer Research</i> , 2023, 83, 3710-3725.	0.9	1
414	Targeting immune checkpoint pathways in melanoma: triumphs and challenges. <i>Future Drug Discovery</i> , 2023, 5, .	2.1	0
415	Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology. <i>European Journal of Cancer</i> , 2023, 193, 113313.	2.8	3
417	Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies. <i>Discover Oncology</i> , 2023, 14, .	2.1	0
418	Management and nursing strategies for different patterns of adverse events in patients with urological cancer treated with immune checkpoint inhibitors. <i>Current Urology</i> , 0, , .	0.6	0
419	Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
420	Acquired bleeding disorders secondary to immune checkpoint inhibitors: a case report and systematic literature review. <i>Blood Coagulation and Fibrinolysis</i> , 2023, 34, 427-431.	1.0	0
421	Highly multiplexed spatial analysis identifies tissue-resident memory TÂcells as drivers of ulcerative and immune checkpoint inhibitor colitis. <i>IScience</i> , 2023, 26, 107891.	4.1	1
425	Atezolizumab-induced myositis in a patient with small-cell lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2024, 30, 220-224.	0.9	1

#	ARTICLE	IF	CITATIONS
426	Treatment-related gastrointestinal adverse events of nivolumab plus ipilimumab in randomized clinical trials: a systematic review and meta-analysis. <i>Future Oncology</i> , 2023, 19, 1865-1875.	2.4	0
427	Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 1689-1708.	3.7	1
428	Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 4049-4064.	4.2	2
429	Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab. <i>Leukemia and Lymphoma</i> , 2023, 64, 2351-2353.	1.3	0
430	Challenges in Management of Immune Checkpoint Inhibitor-Associated Hepatitis. <i>European Medical Journal Gastroenterology</i> , 0, , .	0.0	0
431	Pulmonary Complications of Lung Cancer Treatment. <i>Respiratory Medicine</i> , 2023, , 229-254.	0.1	0
432	Immune Checkpoint Inhibitor-Associated Nephrotoxicity. <i>Nephron</i> , 0, , 1-5.	1.8	0
433	The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman. <i>Cureus</i> , 2023, , .	0.5	0
434	Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis. <i>Current Gastroenterology Reports</i> , 2023, 25, 255-259.	2.5	1
435	Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
436	Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
437	Toxic Neuropathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2023, 29, 1444-1468.	0.8	0
438	Arthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problem. <i>Sovremennaya Revmatologiya</i> , 2023, 17, 112-117.	0.5	0
440	Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2023, 50, 101296.	0.6	0
441	Recent Developments in Endometrial Cancer Research Presented at the Society of Gynecologic Oncology (SGO) Annual Meeting 2023: Interviews with Two Key Opinion Leaders. <i>European Medical Journal Oncology</i> , 0, , 2-10.	0.0	1
442	Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. <i>Clinical and Experimental Nephrology</i> , 0, , .	1.6	1
443	Concomitant Use of Steroids and Immunotherapy in a Patient With Paraneoplastic Dermatomyositis and Gastroesophageal Adenocarcinoma. <i>Cureus</i> , 2023, , .	0.5	0
444	Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study. <i>Journal of Infection and Chemotherapy</i> , 2023, 29, 1038-1045.	1.7	1

#	ARTICLE	IF	CITATIONS
445	The academic point-of-care anti-CD19 chimeric antigen receptor T cell product varnimcabtagene autoleucel (AR10001 cells) shows efficacy and safety in the treatment of relapsed/refractory B cell non-Hodgkin lymphoma. British Journal of Haematology, 2024, 204, 525-533.	2.5	1
446	Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy. Current Neurology and Neuroscience Reports, 0, , .	4.2	0
447	Mechanisms and biomarkers of immune-related adverse events in gastric cancer. European Journal of Medical Research, 2023, 28, .	2.2	0
448	Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects. Oncology Reviews, 0, 17, .	1.8	1
449	Progress in systemic therapy for advanced-stage urothelial carcinoma. Nature Reviews Clinical Oncology, 2024, 21, 8-27.	27.6	1
450	Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events. Pharmaceuticals, 2023, 16, 1610.	3.8	0
451	IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events. Pharmaceuticals, 2023, 16, 1548.	3.8	0
452	Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma. , 2023, 1, .		1
453	Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer. Investigational New Drugs, 2023, 41, 816-824.	2.6	0
454	Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy. Therapeutic Advances in Medical Oncology, 2023, 15, .	3.2	0
455	Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events. Endocrine Journal, 2023, , .	1.6	0
456	The Role of Antibody-Based Therapies in Neuro-Oncology. Antibodies, 2023, 12, 74.	2.5	0
457	PANoptosis: a potential new target for programmed cell death in breast cancer treatment and prognosis. Apoptosis: an International Journal on Programmed Cell Death, 2024, 29, 277-288.	4.9	1
458	Advances in research on molecular markers in immune checkpoint inhibitor-associated myocarditis. , 2023, 2, 439-447.		0
459	The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database. Frontiers in Pharmacology, 0, 14, .	3.5	1
460	Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab – a case report. Frontiers in Immunology, 0, 14, .	4.8	1
461	Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review. Medicina (Lithuania), 2023, 59, 1946.	2.0	1
462	Biomarkers in Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Updated Review of the Literature. Journal of Clinical Medicine, 2023, 12, 7214.	2.4	1

#	ARTICLE	IF	CITATIONS
463	Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Oncology</i> , 0, , 1-9.	1.9	0
464	Unveiling the link between inflammasomes and skin cutaneous melanoma: Insights into expression patterns and immunotherapy response prediction. <i>Mathematical Biosciences and Engineering</i> , 2023, 20, 19912-19928.	1.9	1
465	Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 17597-17605.	2.5	1
466	Comparison of Six Minutes Walk Distances of Cloth, Surgical, and KN95 Mask in Healthy Young Adults. , 2023, , 65-69.		0
467	A Systematic Review of Clinical Practice Guidelines for Managing Pulmonary Toxicities Caused by Immune Checkpoint Inhibitors: Quality of Treatment Recommendations and Differences in Management Strategies Between Guidelines. <i>Clinical Medicine Insights: Oncology</i> , 2023, 17, .	1.3	0
468	Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review. <i>Anti-Cancer Drugs</i> , 2024, 35, 284-287.	1.4	0
469	Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer. <i>Onc Immunology</i> , 2023, 12, .	4.6	0
471	Immune-checkpoint inhibitors and neurological adverse events. <i>Lancet Neurology</i> , The, 2023, 22, 1093-1094.	10.2	0
472	Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report. <i>Cureus</i> , 2023, , .	0.5	0
473	Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study. <i>ESMO Open</i> , 2023, 8, 102070.	4.5	0
474	The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100611.	1.1	0
475	Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges. <i>Journal of Thoracic Oncology</i> , 2024, 19, 395-408.	1.1	0
476	Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
477	Challenges in Management of Immune Checkpoint Inhibitor-Associated Hepatitis. <i>European Medical Journal Gastroenterology</i> , 0, , .	0.0	0
478	Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study. <i>RMD Open</i> , 2023, 9, e003795.	3.8	0
479	All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality. <i>CKJ: Clinical Kidney Journal</i> , 2024, 17, .	2.9	1
480	Pembrolizumab-induced Myopathy with Anti-striated Muscle Antibodies Successfully Treated by Plasma Exchange. <i>Internal Medicine</i> , 2023, 62, 3525-3530.	0.7	1
482	Implanting Iodine-125 Seed Strand Inside the Portal Vein Stent: An Improved Approach to Endovascular Brachytherapy for Treatment of Patients with Hepatocellular Carcinoma and Main Portal Vein Tumor Thrombus. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 2187-2196.	3.7	0

#	ARTICLE	IF	CITATIONS
483	Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects. <i>Seminars in Oncology</i> , 2023, , .	2.2	2
484	Checkpoint inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2023, 2023, 209-215.	2.5	1
485	Diagnosing Beyond Bias: Differentiating Topical Steroid Withdrawal Syndrome From irAE-Induced Adrenal Insufficiency. <i>Cureus</i> , 2023, , .	0.5	0
486	A New Era in Cancer Treatment: Harnessing ZIF-8 Nanoparticles for PD-1 Inhibitor Delivery. <i>Journal of Materials Chemistry B</i> , 0, , .	5.8	0
487	Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study. <i>Current Oncology</i> , 2023, 30, 10396-10407.	2.2	0
488	Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers. <i>Genes</i> , 2023, 14, 2162.	2.4	0
489	Nivolumab-induced diabetes mellitusâ€”a case report with literature review of the treatment options. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
490	Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2023, 12, 225-232.	2.1	0
491	Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. , 2024, , 1-17.		0
492	Cardiotoxicity of Agents Used in Patients With Breast Cancer. <i>JCO Oncology Practice</i> , 2024, 20, 38-46.	2.9	1
493	Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?. <i>Vaccines</i> , 2023, 11, 1843.	4.4	0
494	Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma. <i>Neurological Sciences</i> , 0, , .	1.9	0
495	<sc>IgG4</sc>-related retroperitoneal fibrosis induced by nivolumab and ipilimumab in a patient with nonâ€”small cell lung cancer: A case report. <i>Thoracic Cancer</i> , 0, , .	1.9	1
496	Immune Checkpoint Inhibitor-Induced Liver Injury. <i>Seminars in Liver Disease</i> , 2023, 43, 402-417.	3.6	0
497	Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors. <i>Clinical Colorectal Cancer</i> , 2024, 23, 4-13.	2.3	0
498	Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis. <i>JACC: CardioOncology</i> , 2023, 5, 732-744.	4.0	0
499	Long-term survival and portal vein patency with novel PVTT surgery approach in advanced HCC patients with Vp3/4 PVTT following combination therapy of TKIs and PD-1 inhibitors. <i>BMC Surgery</i> , 2023, 23, .	1.3	0
500	Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0

#	ARTICLE	IF	CITATIONS
501	Nephrotoxicity Associated with Contemporary Renal Cell Carcinoma Regimens: A Systematic Review and Meta-Analysis. <i>Kidney Cancer</i> , 2023, 7, 147-159.	0.4	0
502	Autonomic nervous system involvement in autoimmune encephalitis and paraneoplastic neurological syndromes. <i>Revue Neurologique</i> , 2024, 180, 107-116.	1.5	0
503	Immunotherapy-Induced Hypophysitis Following ICI Treatment With Tislelizumab in an Elderly Patient With Bladder Cancer and Prostate Cancer: A Case Report. <i>Cureus</i> , 2023, , .	0.5	0
504	Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report. <i>JTO Clinical and Research Reports</i> , 2024, 5, 100628.	1.1	0
505	Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy. <i>European Journal of Cancer</i> , 2023, , 113506.	2.8	0
506	Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 0, , .	2.3	1
507	Tissue-Agnostic Cancer Therapy Approvals. <i>Surgical Oncology Clinics of North America</i> , 2024, 33, 243-264.	1.5	0
508	Baseline Circulating Blood Cell Counts and Ratios and Changes Therein for Predicting Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy: A Multicenter, Prospective, Observational, Pan-Cancer Cohort Study with a Gender Perspective. <i>Cancers</i> , 2024, 16, 151.	3.7	0
509	Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. <i>European Journal of Cancer</i> , 2024, 199, 113530.	2.8	0
510	Durvalumab-induced Pure White Cell Aplasia. <i>Journal of Immunotherapy</i> , 2024, 47, 7-9.	2.4	2
511	Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities. <i>Immuno-Oncology Technology</i> , 2024, 21, 100704.	0.3	0
512	Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2024, 13, 307.	2.4	0
513	Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2024, 16, 250.	3.7	0
514	A contemporary update on cancer and takotsubo syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	1
515	Checkpoint inhibitor myocarditis with preceding immunosuppression and tolerance of sequential anthracycline therapy. <i>BMJ Case Reports</i> , 2024, 17, e257357.	0.5	1
516	Novel uses of complement inhibitors in myasthenia gravis” <sc>Two</sc> case reports. <i>Muscle and Nerve</i> , 2024, 69, 368-372.	2.2	0
517	Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. <i>Cancers</i> , 2024, 16, 369.	3.7	0
518	Pulmonary toxicity of immune checkpoint immunotherapy. <i>Journal of Clinical Investigation</i> , 2024, 134, .	8.2	2

#	ARTICLE	IF	CITATIONS
519	Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case report and literature review. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
520	Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4 ⁺ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma. , 2024, 12, e008056.		0
521	Corticosteroid-resistant immune-related adverse events: a systematic review. , 2024, 12, e007409.		0
522	Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC. <i>JTO Clinical and Research Reports</i> , 2024, 5, 100638.	1.1	0
525	Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer. <i>Cancers</i> , 2024, 16, 501.	3.7	0
526	Immune Checkpoint Inhibitor-Associated Myocarditis: A Literature Review. <i>Cureus</i> , 2024, , .	0.5	0
527	Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
528	Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy. <i>Current Cancer Reports</i> , 0, 5, 168-180.	1.2	0
529	Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
531	Multidisciplinary insight for managing immune checkpoint inhibitor-related myocarditis: a case report. <i>Medical Biological Science and Engineering</i> , 2024, 7, 47-50.	0.2	0
532	Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. , 2024, 12, e008232.		0
533	Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature. <i>Frontiers in Medicine</i> , 0, 11, .	2.6	1
534	Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults. <i>Canadian Journal of Neurological Sciences</i> , 0, , 1-21.	0.5	0
535	Crossing the River by Feeling the Stones: Experiences with PD-1 Inhibitors in Geriatric Oncology People, a Case Report and Literature Review. <i>Cancer Management and Research</i> , 0, Volume 16, 87-93.	1.9	0
536	Anticancer drug-induced interstitial lung disease: a critical appraisal of clinical practice guidelines and consensus statements. <i>Expert Opinion on Drug Safety</i> , 0, , 1-9.	2.4	0
537	Metabolic and Toxic Myelopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2024, 30, 199-223.	0.8	0
538	An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 865-876.	3.7	1
539	Immune checkpoint inhibitor-associated cardiovascular toxicities: A review. <i>Heliyon</i> , 2024, 10, e25747.	3.2	0

#	ARTICLE	IF	CITATIONS
540	The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data. <i>Vaccine</i> , 2024, 42, 1498-1505.	3.8	0
541	Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach. <i>Frontiers in Cardiovascular Medicine</i> , 0, 11, .	2.4	0
542	Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Annals of Internal Medicine</i> , 2024, 177, ITC17-ITC32.	3.9	1
543	Achillesâ€™ Heel of currently approved immune checkpoint inhibitors: immune related adverse events. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
544	PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review. <i>International Immunopharmacology</i> , 2024, 129, 111606.	3.8	0
545	The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management. <i>Cancers</i> , 2024, 16, 795.	3.7	0
546	Clinical and translational attributes of immune-related adverse events. <i>Nature Cancer</i> , 2024, 5, 557-571.	13.2	0
547	Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 11, 363-372.	3.7	0
548	Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. , 2024, , 869-884.		0
549	PD-1/PD-L1 inhibitors associated hypophysitis: An analysis from the FAERS database and case reports. <i>Drug Discoveries and Therapeutics</i> , 2024, 18, 34-43.	1.5	0
550	De novo Connective Tissue Disorders as Immune-related Adverse Events. <i>Rheumatic Disease Clinics of North America</i> , 2024, 50, 301-312.	1.9	0
551	Immune checkpoint inhibitors and acute kidney injury. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
552	Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update. <i>Hepatology International</i> , 2024, 18, 384-419.	4.2	0
553	Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy. <i>Expert Review of Clinical Immunology</i> , 0, , 1-21.	3.0	0
555	CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
556	Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data. <i>JCO Clinical Cancer Informatics</i> , 2024, , .	2.1	0
557	Immune checkpoint inhibitors and risk of immune-mediated adverse events: a cohort study comparing extended versus standard interval administration. <i>Clinical and Experimental Medicine</i> , 2024, 24, .	3.6	0
558	Checkpoint Inhibitor-Related Capillary Leak Syndrome (CLS). <i>Cureus</i> , 2024, , .	0.5	0

#	ARTICLE	IF	CITATIONS
559	Immune Checkpoint Inhibitor-induced Inflammatory Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2024, 50, 269-279.	1.9	0
560	Informing immunotherapy with multi-omics driven machine learning. <i>Npj Digital Medicine</i> , 2024, 7, .	10.9	0
561	Central nervous system adverse events of immune checkpoint inhibitors. <i>Current Opinion in Neurology</i> , 2024, 37, 345-352.	3.6	0
562	Drug-induced interstitial lung disease: a narrative review of a clinical conundrum. <i>Expert Review of Respiratory Medicine</i> , 2024, 18, 23-39.	2.5	0
563	Drug-induced Lung Disease in the Oncology Patient. <i>Clinics in Chest Medicine</i> , 2024, , .	2.1	0
564	Complications of <scp>immuno—oncology</scp> care: what urologist should know. <i>BJU International</i> , 2024, 133, 524-531.	2.5	0
565	Anti-integrin $\alpha 6$ autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis. <i>British Journal of Cancer</i> , 2024, 130, 1552-1560.	6.4	0
566	Editorial: Corticosteroids for severe checkpoint inhibitor—induced liver injury—Not one size fits all?. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 905-906.	3.7	0
567	Univariable and multivariable Mendelian randomization study identified the key role of gut microbiota in immunotherapeutic toxicity. <i>European Journal of Medical Research</i> , 2024, 29, .	2.2	0
568	Neurologic manifestations of autoimmunity with immune checkpoint inhibitors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2024, , 449-465.	1.8	0
569	Update on Neuro-ophthalmic Manifestations of Immune Checkpoint Inhibitors. <i>Current Neurology and Neuroscience Reports</i> , 2024, 24, 113-122.	4.2	0
570	Incident Noninfectious Uveitis Risk after Immune Checkpoint Inhibitor Treatment. <i>Ophthalmology</i> , 2024, , .	5.2	0
571	Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
572	Immunohistochemical Evaluation of Renal Biopsy with Anti-PD1 and p53 to Solve the Dilemma between Platinum- and Pembrolizumab-Induced AKI: Case Report and Review. <i>Journal of Clinical Medicine</i> , 2024, 13, 1828.	2.4	0
573	Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective. <i>EClinicalMedicine</i> , 2024, 70, 102536.	7.1	0
575	Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2024, 18, .	0.8	0
576	Immune Checkpoint Inhibitor-induced Myositis. <i>Rheumatic Disease Clinics of North America</i> , 2024, 50, 281-290.	1.9	0
577	Reply to: “irLL or not irLL: That is the question“. <i>Journal of Hepatology</i> , 2024, , .	3.7	0

#	ARTICLE	IF	CITATIONS
578	Engineering nanoparticles for cancer immunotherapy: Current achievements, key considerations and future perspectives. <i>Chemical Engineering Journal</i> , 2024, 486, 150356.	12.7	0
579	Tislelizumab induced dual organs dysfunction in a patient with advanced esophageal squamous cell carcinoma: a case report. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
580	Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0